Fingerprint
Dive into the research topics of 'Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2a antagonist in patients with previously treated advanced clear cell renal cell carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically